5HT1 receptor agonists and metoclopramide for the treatment of migraine
OwnerGeorge H. Sandsinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT1 receptor agonist, and particularly eletriptan, in combination with metoclopramide. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1 receptor agonist and metoclopramide.
Claims7
A pharmaceutical composition for the treatment of migraine comprising metoclopramide, a member of the group consisting of eletriptan, rizatriptan, naratriptan and sumitriptan, and a pharmaceutically acceptable carrier.
A method of treating migraine in a mammal, comprising administering to said mammal antimigraine effective amounts of metoclopramide and a 5HT1 receptor agonist.
Dependencies are inferred from the claim text.